Press coverage about AstraZeneca (NYSE:AZN) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. AstraZeneca earned a daily sentiment score of 0.21 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.0930303368124 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- US FDA Approves TAGRISSO® (osimertinib) As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cancer (prnewswire.com)
- Worth Watching Stocks Buzz – AstraZeneca PLC, NYSE: AZN), Symantec Corporation, (NASDAQ: SYMC) (dailynysenews.com)
- Stocks in the news: Lupin, Fortis Healthcare, Indian Hotels, NHPC, AstraZeneca, Vedanta, Shalby, Andhra Bank (moneycontrol.com)
- A new Highmark contract with a pharma company part of a growing trend in drug purchasing (finance.yahoo.com)
- Global Pulmonary Drugs Market 2018- AstraZeneca plc, Bayer AG, Teva Pharmaceutical Industries Ltd (theanalystfinancial.com)
Several research firms have issued reports on AZN. ValuEngine downgraded AstraZeneca from a “strong-buy” rating to a “buy” rating in a report on Wednesday, March 7th. Zacks Investment Research downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Monday, April 9th. BMO Capital Markets set a $40.00 price objective on AstraZeneca and gave the stock a “buy” rating in a report on Tuesday, February 20th. Jefferies Group upgraded AstraZeneca from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $28.43 to $36.70 in a report on Monday, March 19th. Finally, Sanford C. Bernstein boosted their price objective on AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. Three research analysts have rated the stock with a sell rating, five have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. AstraZeneca currently has a consensus rating of “Buy” and a consensus price target of $38.12.
AstraZeneca (NYSE:AZN) last released its earnings results on Friday, February 2nd. The company reported $1.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.86. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. The company had revenue of $5.78 billion for the quarter, compared to analysts’ expectations of $5.49 billion. During the same quarter in the previous year, the business posted $1.21 EPS. The business’s revenue for the quarter was up 3.4% on a year-over-year basis. equities research analysts anticipate that AstraZeneca will post 1.69 earnings per share for the current year.
The firm also recently announced a semiannual dividend, which was paid on Monday, March 19th. Shareholders of record on Friday, February 16th were paid a dividend of $0.95 per share. The ex-dividend date was Thursday, February 15th. This represents a yield of 5.62%. AstraZeneca’s dividend payout ratio (DPR) is presently 32.01%.
ILLEGAL ACTIVITY WARNING: This report was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://weekherald.com/2018/04/18/astrazeneca-azn-receives-daily-coverage-optimism-rating-of-0-21.html.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.